OncoVent, a Subsidiary of Hepalink, Enters into a License and Distribution Agreement with Orient EuroPharma for the Immunotherapeutic Candidate Oregovomab

Posted on by

SHENZHEN, China, March 28, 2023 /PRNewswire/ — OncoVent Co., Ltd. (“OncoVent”), a majority-controlled subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “Company”), yesterday entered into a license agreement with Orient EuroPharma Co., Ltd. (“OEP”). According to the…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.